WNT/β-Catenin-Mediated Resistance to Glucose Deprivation in Glioblastoma Stem-like Cells.
WNT/β-catenin
cancer metabolism
cancer stem-like cells
glioblastoma
glucose starvation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Jun 2022
28 Jun 2022
Historique:
received:
12
05
2022
revised:
22
06
2022
accepted:
23
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
10
7
2022
Statut:
epublish
Résumé
Isocitrate dehydrogenase (IDH)-wildtype glioblastoma is the most common primary malignant brain tumor. It is associated with a particularly poor prognosis, as reflected by an overall median survival of only 15 months in patients who undergo a supramarginal surgical reduction of the tumor mass followed by combined chemoradiotherapy. The highly malignant nature of IDH-wildtype glioblastoma is thought to be driven by glioblastoma stem-like cells (GSCs) that harbor the ability of self-renewal, survival, and adaptability to challenging environmental conditions. The wingless (WNT) signaling pathway is a phylogenetically highly conserved stemness pathway, which promotes metabolic plasticity and adaptation to a nutrient-limited tumor microenvironment. To unravel the reciprocal regulation of the WNT pathway and the nutrient-limited microenvironment, glioblastoma cancer stem-like cells were cultured in a medium with either standard or reduced glucose concentrations for various time points (24, 48, and 72 h). Glucose depletion reduced cell viability and facilitated the survival of a small population of starvation-resistant tumor cells. The surviving cells demonstrated increased clonogenic and invasive properties as well as enhanced chemosensitivity to pharmacological inhibitors of the WNT pathway (LGK974, berberine). Glucose depletion partially led to the upregulation of WNT target genes such as
Identifiants
pubmed: 35804936
pii: cancers14133165
doi: 10.3390/cancers14133165
pmc: PMC9264876
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2017 Aug 18;8(43):74661-74672
pubmed: 29088815
Nat Rev Dis Primers. 2015 Jul 16;1:15017
pubmed: 27188790
Front Plant Sci. 2022 Jan 18;12:756505
pubmed: 35116048
Organogenesis. 2008 Apr;4(2):68-75
pubmed: 19279717
Int J Mol Sci. 2022 Apr 20;23(9):
pubmed: 35562953
EMBO J. 2010 Jun 16;29(12):1946-7
pubmed: 20551969
Integr Biol (Camb). 2012 May;4(5):480-93
pubmed: 22402787
Int J Mol Sci. 2019 Jan 14;20(2):
pubmed: 30646511
Oncol Rep. 2020 Dec;44(6):2325-2336
pubmed: 33125150
Oncogene. 2022 Jan;41(5):613-621
pubmed: 34764443
Oncotarget. 2016 Nov 8;7(45):73414-73431
pubmed: 27705917
Cell Death Dis. 2020 Sep 17;11(9):771
pubmed: 32943609
Brain Pathol. 2015 Nov;25(6):724-32
pubmed: 25521330
Cells. 2021 Sep 07;10(9):
pubmed: 34571995
J Biol Chem. 2002 Aug 23;277(34):30409-12
pubmed: 12087111
Biomed Pharmacother. 2021 Dec;144:112278
pubmed: 34628166
Cancer Metab. 2018 Apr 03;6:3
pubmed: 29619216
EMBO J. 2019 Jan 15;38(2):
pubmed: 30425074
Front Immunol. 2019 Dec 16;10:2872
pubmed: 31921137
Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
Curr Genomics. 2020 Jan;21(1):34-36
pubmed: 32655296
Gynecol Oncol. 2015 Sep;138(3):668-75
pubmed: 26135947
Cells. 2019 Sep 19;8(9):
pubmed: 31546785
J Biol Chem. 2011 May 6;286(18):16426-34
pubmed: 21454484
Endocrinology. 2018 Jan 1;159(1):272-284
pubmed: 29077850
Front Oncol. 2019 Mar 06;9:118
pubmed: 30895167
Cancers (Basel). 2021 Nov 29;13(23):
pubmed: 34885110
Oncotarget. 2018 Apr 27;9(32):22703-22716
pubmed: 29854309
Front Pharmacol. 2021 Nov 03;12:762654
pubmed: 35370628
J Cancer. 2019 Jun 9;10(16):3789-3797
pubmed: 31333796
Biochem Biophys Res Commun. 2010 Apr 23;395(1):146-51
pubmed: 20361929
Cell Death Dis. 2015 Jul 02;6:e1805
pubmed: 26136078
J Biol Chem. 2015 Apr 10;290(15):9863-73
pubmed: 25691573
Int J Mol Sci. 2021 Aug 05;22(16):
pubmed: 34445128
Cancer Metab. 2016 Oct 3;4:20
pubmed: 27729975
Int J Mol Sci. 2022 Jan 24;23(3):
pubmed: 35163235
Hum Exp Toxicol. 2011 Oct;30(10):1701-9
pubmed: 21339255
Cell Death Discov. 2018 Dec 5;4:110
pubmed: 30534418
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076